Anti-Müllerian hormone receptor 2 extracellular domain vaccine

The **Anti-Müllerian hormone receptor 2 extracellular domain vaccine** (AMHR2-ED vaccine) is a preventive immunotherapy targeting the extracellular domain of AMHR2, a protein expressed in ~90-92% of epithelial ovarian carcinomas (EOCs) but minimally in postmenopausal ovaries, minimizing autoimmunity risk. Vaccination induces AMHR2-ED-specific IgG antibodies via CD4+ T cell help, agonizing a Bax/caspase-3-dependent proapoptotic cascade that inhibits EOC tumor growth and enhances survival in mouse models. Developed by **Cleveland Clinic** in collaboration with the **National Cancer Institute**, it uses safe squalene-based adjuvants like AddaVax (MF59-like) instead of CFA for human trials, with **Anixa Biosciences** holding exclusive worldwide rights; preclinical data support phase 1 trials for high-risk women (e.g., BRCA mutations).

Other names

AMHR2-ED vaccineAMHR-2-ED vaccineAMHR 2-ED vaccine